ArticleInterdisciplinary cardiovascular and thoracic surgery2025
Subgroup and Prognostic Factor Analysis in T4 Lung Cancer Based on the 9th Tumour-Node-Metastasis Classification.
Article in Interdisciplinary cardiovascular and thoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Not All T4 Patients Should Be Considered Equal: Non-Small Cell Lung Cancer Heterogeneity and Surgical Outcome.Annals of thoracic surgery short reports · 2026Article
- Surgery-based treatment and prognostic factors in patients with limited-stage small cell lung cancer: a retrospective cohort study.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesT4 non-small-cell lung cancer comprises a biologically and anatomically heterogeneous group. The 9th edition of the Tumour-Node-Metastasis staging system introduced refined T4 definitions and subdivided N2 disease into single- and multi-station involvement. This study aimed to assess long-term survival and prognostic factors in surgically treated T4 non-small-cell lung cancer patients, focusing on T4 subgroups and nodal status.
methodsWe retrospectively analysed patients who underwent resection for pathologically confirmed T4 non-small cell lung cancer between 2006 and 2024. Patients were categorized based on T4 criteria: tumour diameter >7 cm, adjacent structure invasion, or multiple T4 features. Survival outcomes were assessed using Kaplan-Meier, Aalen-Johansen and Cox regression analyses.
resultsA total of 191 patients were analysed. The 5-year overall survival rate was 34.1%, varying across subgroups: 38.7% (size), 29.9% (invasion), and 6.1% (multiple criteria) (P < .001). Adjuvant chemotherapy was associated with improved overall survival (hazard ratio [HR]: 0.511; P = .001), while N2 disease (HR: 1.750; P = .012) and multiple T4 features (HR: 2.590; P < .001) predicted worse outcomes. Similar patterns were observed in recurrence-free survival. N2 involvement was particularly adverse in the invasion group.
conclusionsT4 aetiology and nodal status significantly impact survival following surgery. These findings support the prognostic utility of the 9th Tumour-Node-Metastasis edition and underscore the value of tailored surgical strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.